Tislelizumab use in European patients with NSCLC or ES-SCLC in routine care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study collects real-world data on treatment patterns and outcomes for patients with advanced NSCLC or extensive-stage SCLC who receive tislelizumab as part of standard care in Europe. Data will come from routine clinical practice across several hospitals and will reflect how the drug is used outside of controlled trials. The goal is to describe how patients fare on tislelizumab in real-world settings and to identify patterns that may inform future care. The study does not assign treatments or change medical decisions; it observes treatments already chosen by treating physicians. Results may help clinicians understand where tislelizumab fits in current practice and generate hypotheses for future research.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants are eligible to be included in the study only if they meet all the following criteria:

  1. Participants or their legal representative must sign written inform consent form (ICF)
  2. Participants receive tislelizumab as part of routine clinical practice as determined by the treating physician per standard of care and in accordance with the SmPC, within the approved indications in the 4 cohorts described.

Note: The decision to treat the patient with a tislelizumab-based regimen, as per its authorized indication, must have been made by the treating physician prior to and independent of the patient's consideration for participation in this study.

Exclusion Criteria:

* Participants are excluded from the study if they meet any of the following criteria:

  1. Participants who are unable to understand all implications of study participation.
  2. Participants who have contraindications for treatment with tislelizumab in the investigator's opinion or have any contraindication as listed in the SmPC of tislelizumab.
  3. Participants who are deemed ineligible according to the investigator's opinion and the SmPC of tislelizumab.

Where it's running

• Hospital Universitario Reina Sofía
  Córdoba, Spain Recruiting
• Hospital Universitario de Jaén
  Jaén, Spain Recruiting
• Hospital Universitario Lucus Augusti (HULA)
  Lugo, Spain Recruiting
• Hospital de Segovia
  Segovia, Spain Recruiting
• Hospital General de Segovia
  Segovia, Spain Recruiting
• Hospital de Sagunto
  Valencia, Spain Recruiting

Study contacts

• Study coordinator: Study Director
• Email: clinicaltrials@beonemed.com
• Phone: 1-877-828-5568

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QLC5508 plus QL2107 vs tislelizumab plus platinum chemotherapy as first treatment for extensive-stage small cell lung cancer

  This phase 3 trial tests whether QLC5508 with QL2107 works better than tislelizumab with platinum chemotherapy for adults with untreated extensive-stage small cell lung cancer.

  Recruiting Phase 3 Qilu Pharmaceutical Co., Ltd. · Shanghai · NCT07802821

• BL-B01D1 plus tislelizumab vs platinum-based chemo plus tislelizumab as first-line treatment for extensive-stage small cell lung cancer

  This trial tests whether adding BL-B01D1 to tislelizumab works better than platinum-containing chemotherapy with tislelizumab for adults with extensive-stage small cell lung cancer.

  Recruiting at 2 sites Phase 3 Sichuan Baili Pharmaceutical Co., Ltd. · Zhengzhou, Henan and 1 other locations · NCT07502300

• Using T-cell receptor patterns to predict response to first-line tislelizumab plus chemotherapy in extensive-stage small-cell lung cancer

  This will test whether patterns in patients' T-cell receptors can predict how well first-line tislelizumab plus chemotherapy works for people with extensive-stage small-cell lung cancer.

  Recruiting Henan Cancer Hospital · Zhengzhou, Henan · NCT07244016

• Combining Tislelizumab with chemotherapy and radiotherapy for extensive-stage small-cell lung cancer

  This study is testing if combining a new drug called Tislelizumab with chemotherapy and radiation can help people with extensive-stage small-cell lung cancer feel better and improve their health.

  Recruiting at 6 sites Phase 2 Second Hospital of Shanxi Medical University · Jincheng, Shanxi and 5 other locations · NCT06536868

• Tislelizumab with Tofacitinib and Docetaxel for NSCLC After First-Line Immunotherapy

  This study tests whether adding tofacitinib to tislelizumab and docetaxel helps people with locally advanced or metastatic NSCLC who did not respond to first-line immunotherapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07925866

• SYS6010 plus Enlonstobart for recurrent or metastatic nasopharyngeal cancer in patients who have not had prior systemic therapy

  This trial tests whether SYS6010 with Enlonstobart works better than Tislelizumab with gemcitabine and cisplatin for people whose recurrent or metastatic nasopharyngeal cancer has not yet received systemic treatment.

  Recruiting Phase 3 CSPC Megalith Biopharmaceutical Co.,Ltd. · Guangzhou, Guangzhou · NCT07925021

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.